Achiron Asaf
Resident, Department of Ophthalmology, Edith Wolfson Medical Center Holon, Israel.
J Curr Glaucoma Pract. 2017 May-Aug;11(2):63-66. doi: 10.5005/jp-journals-10028-1225. Epub 2017 Aug 5.
The current treatment for posterior capsular opacification (PCO), neodymium-doped yttrium aluminum garnet (Nd:YAG) laser capsulotomy, may lead to increased intraocular pressure (IOP). Our aim was to survey routines in the management of IOP spikes and to identify the rate of IOP spikes following prophylactic apraclonidine treatment.
A survey questionnaire among ophthalmologists and a retrospective registry review was used. Patients were administered apraclonidine 0.5% prior to capsulotomy. The IOP was measured before and 1 hour postprocedure.
A total of 71% of responders (n = 45) routinely prescribe topical IOP-lowering medication and 82% routinely measure IOP before or after capsulotomy. The registry analysis included 87 eyes of 75 patients. Mean IOP decreased by 0.9 ± 3.3 mm Hg (p = 0.01, range: -6 to 10) following capsulotomy. No patient reached IOP values above 21 mm Hg following the procedure, with 3.4 and 1.1% of patients demonstrating an IOP elevation of more than 3 and 5 mm Hg respectively. No association was found between number of laser shots, mean laser power, or comorbid conditions, such as diabetes, hypertension, or glaucoma status with posttreatment IOP.
Most ophthalmologists surveyed routinely prescribe prophylactic IOP-lowering medication and measure IOP before or after capsulotomy. Mean IOP remained clinically stable following capsulotomy with prophylactic apraclonidine instillation, and no patient reached IOP values above 21 mm Hg. Differences in laser delivery or comorbid conditions were not associated with posttreatment IOP. Considering that no patient demonstrated a clinically significant IOP spike following prophylactic apraclonidine instillation, perhaps routine measurement of IOP following primary Nd:YAG laser may be reserved for high-risk patients only.
In this work, we showed the prophylactic effect of apraclonidine 0.5% and suggest that measuring IOP after the procedure is necessary only in certain high-risk cases, possibly helping to reduce workload and patient waiting time and improving quality of service.
Achiron A. Intraocular Pressure Spikes following Neodymium-doped Yttrium Aluminum Garnet Laser Capsulotomy: Current Prevalence and Management in Israel. J Curr Glaucoma Pract 2017;11(2):63-66.
后囊膜混浊(PCO)目前的治疗方法——钕掺杂钇铝石榴石(Nd:YAG)激光囊切开术,可能会导致眼压(IOP)升高。我们的目的是调查眼压峰值管理的常规做法,并确定预防性使用阿可乐定治疗后眼压峰值的发生率。
采用对眼科医生的调查问卷和回顾性登记审查。在囊切开术前给患者使用0.5%的阿可乐定。在手术前和术后1小时测量眼压。
共有71%的应答者(n = 45)常规开具局部降眼压药物,82%的应答者常规在囊切开术前或术后测量眼压。登记分析纳入了75例患者的87只眼。囊切开术后平均眼压降低了0.9±3.3 mmHg(p = 0.01,范围:-6至10)。术后没有患者的眼压值超过21 mmHg,分别有3.4%和1.1%的患者眼压升高超过3和5 mmHg。未发现激光脉冲次数、平均激光功率或合并症(如糖尿病、高血压或青光眼状态)与治疗后眼压之间存在关联。
大多数接受调查的眼科医生常规开具预防性降眼压药物,并在囊切开术前或术后测量眼压。预防性滴注阿可乐定进行囊切开术后,平均眼压在临床上保持稳定,没有患者的眼压值超过21 mmHg。激光操作或合并症的差异与治疗后眼压无关。鉴于预防性滴注阿可乐定后没有患者出现具有临床意义的眼压峰值,或许原发性Nd:YAG激光术后的眼压常规测量可能仅适用于高危患者。
在本研究中,我们展示了0.5%阿可乐定的预防作用,并建议仅在某些高危病例中术后测量眼压,这可能有助于减少工作量和患者等待时间,并提高服务质量。
阿奇龙A。钕掺杂钇铝石榴石激光囊切开术后的眼压峰值:以色列目前的患病率及管理。《当代青光眼实践杂志》2017;11(2):63 - 66。